Insider Buying: Diaceutics (LON:DXRX) Insider Acquires £150.15 in Stock

Diaceutics PLC (LON:DXRX) insider Nick Roberts bought 91 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were acquired at an average cost of GBX 165 per share, with a total value of £150.15.

Diaceutics Price Performance

LON DXRX opened at GBX 165.96 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 9.92 and a current ratio of 4.85. The business’s fifty day moving average is GBX 143.90 and its two-hundred day moving average is GBX 129.89. The stock has a market capitalization of £140.31 million, a P/E ratio of -8,215.84 and a beta of 0.58. Diaceutics PLC has a 1 year low of GBX 106 and a 1 year high of GBX 167.

Diaceutics (LON:DXRX) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (2.84) earnings per share (EPS) for the quarter. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%. On average, research analysts forecast that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on DXRX. Royal Bank Of Canada decreased their target price on Diaceutics from GBX 195 to GBX 185 and set an “outperform” rating on the stock in a research report on Thursday, July 10th. Canaccord Genuity Group reissued a “buy” rating and set a GBX 180 price objective on shares of Diaceutics in a report on Tuesday, July 22nd. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Diaceutics has an average rating of “Buy” and an average target price of GBX 175.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.